Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CONNEX-X long-term safety extension of iclepertin in schizophrenia
jRCT2061220034Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jun 2022
- Modality
- Classical Binding Small Molecules → Small Molecules
01
Overview
Open-label, single-arm trial of iclepertin in schizophrenia, sponsored by Boehringer Ingelheim. Primary endpoint: Treatment-emergent adverse events. Started Jun 2022; status: completed.
02
Drugs
iclepertin
03
Conditions
schizophrenia
Beyond the preview
Go deeper on jRCT2061220034.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061220034.